Abstract
AIM: To evaluate the clinical effects of bevacizumab combined with chemotherapy in the treatment of advanced colorectal cancer.
METHODS: One hundred and seventy-eight patients with advanced colorectal cancer were divided into either an observation group (85 cases) or a control group (93 cases). The observation group was treated by bevacizumab combined with chemotherapy, and the control group was treated by XELOX chemotherapy. The clinical effects, side effects, and quality of life were compared for the two groups.
RESULTS: The response rate for the observation group was significantly better than that for the control group (67.06% vs 47.31%, P < 0.05). The rate of bone marrow suppression for the observation group was significantly lower than that for the control group (26.32% vs 50.54%, P < 0.05). There were no significant differences in the rates of bone marrow suppression, neurotoxicity, gastrointestinal reaction, liver and kidney toxicity, or immune system disorders (25.88% vs 26.88%, 17.65% vs 20.43%, 20.00% vs 23.66%, 15.29% vs 11.83%, 11.76% vs 8.60%, P > 0.05). The scores of quality of life for the observation group posttreatment were similar to prior-treatment values (65.62 ± 3.34 vs 67.83 ± 4.06, 67.67 ± 3.46 vs 69.26 ± 3.98, 66.15 ± 3.52 vs 68.11 ± 3.96, 66.58 ± 3.51 vs 68.02 ± 4.02, 66.83 ± 3.55 vs 68.39 ± 3.81, P > 0.05). The scores of quality of life for the control group were significantly lower after treatment than prior-treatment (51.57 ± 3.26 vs 67.89 ± 4.11, 54.62 ± 3.31 vs 69.30 ± 3.89, 53.24 ± 3.28 vs 68.15 ± 3.92, 52.26 ± 3.22 vs 67.97 ± 4.11, 53.16 ± 3.28 vs 68.41 ± 3.80, P < 0.05).
CONCLUSION: Bevacizumab combined with chemotherapy has better clinical effects than chemotherapy alone in the treatment of advanced colorectal cancer, without significant impact on side effects and quality of life.
Collapse